Enhancing Advance Care Planning for Latino Cancer Patients
Latinos' Beliefs and Communication About Advance Care Planning
This study tests a coaching program to help Latino cancer patients better understand and engage in planning their future healthcare decisions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (New York, New York and 3 other locations) |
| Trial ID | NCT04889144 on ClinicalTrials.gov |
What this trial studies
This intervention tests the effectiveness of the PLAN intervention, which consists of three coaching sessions aimed at improving Latino cancer patients' understanding and engagement in advance care planning. Patients are randomized into two groups: one receiving the PLAN intervention and the other receiving usual care. The study follows participants for one week and three months after the intervention to assess outcomes related to advance care planning discussions with loved ones and healthcare providers.
Who should consider this trial
Good fit: Ideal candidates are Latino patients with locally advanced or metastatic cancer who can provide informed consent.
Not a fit: Patients who are not fluent in English or Spanish, severely cognitively impaired, or currently receiving palliative care may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve Latino cancer patients' ability to communicate their care preferences and needs.
How similar studies have performed: Other studies have shown promise in using communication interventions to enhance advance care planning, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Identifying ethnically as Latino. * Locally advanced or metastatic cancer and/or have experienced disease progression on at least first-line chemotherapy. * Ability to provide informed consent. Exclusion Criteria: * Not fluent in English or Spanish. * Severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of \>= 6 to be delivered by trained study research staff during screening). * Too ill or weak to complete the interviews (as judged by interviewer). * Currently receiving palliative care/hospice at the time of enrollment (to allow prediction of \[advanced care planning\] ACP). * Children and young adults under age 18. * Patients deemed inappropriate for the study by their treating oncologist.
Where this trial is running
New York, New York and 3 other locations
- Weill Cornell Medicine — New York, New York, United States (Terminated)
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas, United States (Recruiting)
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (Recruiting)
- Confluence Health — Wenatchee, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Megan J Shen, PhD — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Claudia De Los Santos, BS
- Email: cdelossa@fredhutch.org
- Phone: 206-667-1565
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.